Fidelity Investments
EGRX

Fidelity Investments’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Fidelity Investments’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28,348
Closed -$106K – 5919
2024
Q3 		$106K Sell
28,348
-815
-3% -$3.89K ﹤0.01% 3449
2024
Q2 		$163K Buy
29,163
+7,060
+32% +$30.7K ﹤0.01% 3106
2024
Q1 		$116K Buy
22,103
+1,386
+7% +$7.61K ﹤0.01% 3219
2023
Q4 		$108K Buy
20,717
+1,685
+9% +$16.6K ﹤0.01% 3186
2023
Q3 		$300K Sell
19,032
-602
-3% -$10.8K ﹤0.01% 2758
2023
Q2 		$382K Buy
19,634
+19,048
+3,251% +$452K ﹤0.01% 2741
2023
Q1 		$16.6K Buy
586
+378
+182% +$11.2K ﹤0.01% 3921
2022
Q4 		$6.08K Sell
208
-12,693
-98% -$404K ﹤0.01% 4189
2022
Q3 		$340K Sell
12,901
-20,979
-62% -$770K ﹤0.01% 2896
2022
Q2 		$1.5M Buy
33,880
+20,927
+162% +$961K ﹤0.01% 2571
2022
Q1 		$641K Buy
12,953
+12,853
+12,853% +$617K ﹤0.01% 2913
2021
Q4 		$5K Sell
100
-7
-7% -$363 ﹤0.01% 3833
2021
Q3 		$6K Sell
107
-72
-40% -$3.54K ﹤0.01% 3766
2021
Q2 		$7K Buy
179
+29
+19% +$1.2K ﹤0.01% 3657
2021
Q1 		$6K Buy
150
+50
+50% +$2.32K ﹤0.01% 3523
2020
Q4 		$5K Hold
100
– – ﹤0.01% 3459
2020
Q3 		$4K Hold
100
– – ﹤0.01% 3376
2020
Q2 		$5K Sell
100
-48,290
-100% -$2.41M ﹤0.01% 3257
2020
Q1 		$2.23M Buy
48,390
+182
+0.4% +$9.13K ﹤0.01% 2166
2019
Q4 		$2.9M Sell
48,208
-34,518
-42% -$2.06M ﹤0.01% 2170
2019
Q3 		$4.68M Sell
82,726
-29,199
-26% -$1.64M ﹤0.01% 2077
2019
Q2 		$6.23M Sell
111,925
-52,200
-32% -$2.72M ﹤0.01% 2029
2019
Q1 		$8.29M Sell
164,125
-3,200
-2% -$142K ﹤0.01% 1926
2018
Q4 		$6.74M Sell
167,325
-71,096
-30% -$3.66M ﹤0.01% 1942
2018
Q3 		$16.5M Sell
238,421
-50,088
-17% -$3.8M ﹤0.01% 1759
2018
Q2 		$21.8M Sell
288,509
-32,500
-10% -$2.04M ﹤0.01% 1685
2018
Q1 		$16.9M Buy
321,009
+17
+0% +$989 ﹤0.01% 1787
2017
Q4 		$17.1M Hold
320,992
– – ﹤0.01% 1780
2017
Q3 		$19.1M Sell
320,992
-8,503
-3% -$514K ﹤0.01% 1711
2017
Q2 		$26M Buy
329,495
+8,503
+3% +$695K ﹤0.01% 1570
2017
Q1 		$26.6M Buy
320,992
+228,981
+249% +$17M ﹤0.01% 1573
2016
Q4 		$7.3M Buy
+92,011
New +$6.68M ﹤0.01% 2072
2016
Q2 		– Sell
-144,650
Closed -$5.86M – 2710
2016
Q1 		$5.86M Buy
144,650
+99,100
+218% +$6.29M ﹤0.01% 2116
2015
Q4 		$4.04M Buy
45,550
+30,400
+201% +$2.4M ﹤0.01% 2255
2015
Q3 		$1.12M Buy
+15,150
New +$1.26M ﹤0.01% 2505

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Fidelity Investments's EGRX Position: Q4 2024 in Review

Fidelity Investments sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 28,348 shares — an estimated $106K sold.

Fidelity Investments first reported a position in EGRX in Q3 2015 and held it in 35 quarters. The position peaked at $26.6M in Q1 2017. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Fidelity Investments reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Fidelity Investments sold 28,348 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $106K.
  • Fidelity Investments first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 35 quarters.
  • Fidelity Investments's Eagle Pharmaceuticals, Inc. position peaked at $26.6M in Q1 2017.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Fidelity Investments's 13F filing for Q4 2024, filed 13 Feb 2025.